Posters and Publications

Scientific Presentations and Publications

Edgewise presents original research on its science and therapeutic development at scientific and medical conferences, as well as in published peer-reviewed scientific journals.

Please contact us if you would like to learn more about the research presented here.

June 2022

EDG-5506: A Novel Approach to Protect Muscle in Duchenne Muscular Dystrophy

2022 PPMD Annual Conference

June 2022

EDG-5506: A Novel Approach to Protect Muscle in Becker Muscular Dystrophy

2022 PPMD Annual Conference

June 2022

Insights into the Becker Muscular Dystrophy Experience from the Duchenne Registry, a Comprehensive Registry for Duchenne and Becker Muscular Dystrophy

2022 PPMD Annual Conference

June 2022

EDG-5506: A Novel Approach to Protect Muscle in Duchenne and Becker Muscular Dystrophy

2022 PPMD Annual Conference

June 2022

Understanding the Becker Muscular Dystrophy (BMD) Experience from the Patient Perspective: It’s More Than Mild Duchenne

2022 PPMD Annual Conference

June 2022

Taking a New Approach to Protect Muscle in Duchenne and Becker Muscular Dystrophy: EDG-5506

New Directions Biology and Disease of Skeletal Muscle Conference

June 2022

Use of an Exercise Challenge System to Define a Universal Proteomic Signature of Muscle Injury in a Diverse Set of Adult Individuals with Inherited Myopathy

New Directions Biology and Disease of Skeletal Muscle Conference 2022

June 2022

Short-Term Proteomic Responses to the Fast Skeletal Myosin Inhibitor EDG-5506 in Becker Muscular Dystrophy

New Directions Biology and Disease of Skeletal Muscle Conference 2022

June 2022

EDG-5506 is a Selective Inhibitor of Fast Skeletal Muscle Myosin

New Directions Biology and Disease of Skeletal Muscle Conference 2022

June 2022

Skeletal myosin inhibitor EDG-5506 protects dystrophic muscle from contraction induced injury

New Directions Biology and Disease of Skeletal Muscle Conference 2022

May 2022

Manipulating the Dark Side of Muscle Adaptation for Therapeutic Gain

13th Annual GoldLab Symposium

March 2022

EDG-5506 Targets Fast Skeletal Myosin to Protect Dystrophic Muscle and Reduce Muscle Damage Biomarkers in a Phase 1 Trial in Becker Muscular Dystrophy

2022 MDA Clinical and Scientific Conference

March 2022

EDG 5506 Targets Fast Skeletal Myosin to Protect Dystrophic Muscle and Reduce Muscle Damage Biomarkers in a Phase 1 Trial in Becker Muscular Dystrophy

2022 MDA Clinical and Scientific Conference

March 2022

Modulating fast skeletal muscle contraction as a novel therapeutic strategy for muscular dystrophy

2022 MDA Clinical and Scientific Conference

March 2022

Use of an exercise challenge system to define a universal proteomic signature of muscle injury in a diverse set of adult individuals with inherited myopathy

2022 MDA Clinical and Scientific Conference

March 2022

A Novel Approach to Protecting Dystrophic Muscle by Targeting Fast Muscle Myosin: EDG-5506

2022 MDA Clinical and Scientific Conference

February 2022

Direct and Selective Myosin-Inhibition Stabilizes the Super-Relaxed State of Myosin and Blunts Post-Tetanic Potentiation in Fast-Skeletal Muscle

2022 Annual Meeting of the Biophysical Society

June 2021

Selective Inhibition of Fast Skeletal Muscle Myosin as a Novel Therapeutic Strategy for Muscular Dystrophy

2021 New Directions in Biology and Disease of Skeletal Muscle Conference

June 2021

Development of a Novel Therapeutic for Duchenne, Becker and other Muscular Dystrophies

2021 PPMD Annual Conference

May 2021

Elevation of fast but not slow troponin I in the circulation of patients with Becker and Duchenne muscular dystrophy

Muscle & Nerve, March 8, 2021